Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease

Shale, M. J., Riley, S. A. · 2003 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Non‐compliance with maintenance mesalazine therapy may be a risk factor for relapse in inflammatory bowel disease, but the prevalence and determinants of non‐compliance are unknown. Aim: To study the prevalence and determinants of non‐compliance in patients with inflammatory bowel disease. Methods: Out‐patients receiving delayed‐release mesalazine were studied. Compliance was determined by direct enquiry and by analysis of urine samples for 5‐aminosalicylic acid/N‐acetyl‐5‐aminosalicylic acid. Potential determinants of compliance were assessed. Results: Ninety‐eight patients were studied. Forty‐two patients (43%) reported taking < 80% of their prescribed dose. Logistic regression revealed the independent predictors of non‐compliance to be three‐times daily dosing [odds ratio (OR), 3.1; 95% confidence interval (CI), 1.8–8.4] and full‐time employment (OR, 2.7; 95% CI, 1.1–6.9). Urine from 12 patients (12%) contained no detectable 5‐aminosalicylic acid/N‐acetyl‐5‐aminosalicylic acid, and 18 patients (18%) had levels below those expected. Depression was the only independent predictor of complete non‐compliance (OR, 10.5; 95% CI, 1.8–79.0), and three‐times daily dosing was the only independent predictor of partial non‐compliance (OR, 3.7; 95% CI, 1.8–8.9). Self‐reporting correctly identified 66% of patients judged to be non‐compliant on urinary drug measurement. Conclusions: Non‐compliance with maintenance mesalazine therapy is common in patients with inflammatory bowel disease. Three‐times daily dosing and full‐time employment are predictors of partial non‐compliance, whilst depression is associated with complete non‐compliance. Self‐reporting detects most non‐compliant patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2003.01648.x

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 256

Metadata

Authors
Shale, M. J., & Riley, S. A.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2003-07
Volume
18
Issue
2
Pages
191-198
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1969818489
Cited by
256
References
43
FWCI
7.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease. https://app.cochat.ai/papers/10.1046/j.1365-2036.2003.01648.x
The paper
Shale, M. J., & Riley, S. A. (2003). Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2003.01648.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.